160 related articles for article (PubMed ID: 24135197)
1. Olanzapine-induced hyperglycemia: possible involvement of histaminergic, dopaminergic and adrenergic functions in the central nervous system.
Ikegami M; Ikeda H; Ohashi T; Kai M; Osada M; Kamei A; Kamei J
Neuroendocrinology; 2013; 98(3):224-32. PubMed ID: 24135197
[TBL] [Abstract][Full Text] [Related]
2. Olanzapine increases hepatic glucose production through the activation of hypothalamic adenosine 5'-monophosphate-activated protein kinase.
Ikegami M; Ikeda H; Ohashi T; Ohsawa M; Ishikawa Y; Kai M; Kamei A; Kamei J
Diabetes Obes Metab; 2013 Dec; 15(12):1128-35. PubMed ID: 23782571
[TBL] [Abstract][Full Text] [Related]
3. Olanzapine induces glucose intolerance through the activation of AMPK in the mouse hypothalamus.
Ikegami M; Ikeda H; Ishikawa Y; Ohsawa M; Ohashi T; Kai M; Kamei A; Kamei J
Eur J Pharmacol; 2013 Oct; 718(1-3):376-82. PubMed ID: 23973646
[TBL] [Abstract][Full Text] [Related]
4. Hypothalamic histamine H1 receptor-AMPK signaling time-dependently mediates olanzapine-induced hyperphagia and weight gain in female rats.
He M; Zhang Q; Deng C; Wang H; Lian J; Huang XF
Psychoneuroendocrinology; 2014 Apr; 42():153-64. PubMed ID: 24636512
[TBL] [Abstract][Full Text] [Related]
5. Involvement of dopamine D1 receptors and alpha1-adrenoceptors in the antidepressant-like effect of chlorpheniramine in the mouse tail suspension test.
Hirano S; Miyata S; Onodera K; Kamei J
Eur J Pharmacol; 2007 May; 562(1-2):72-6. PubMed ID: 17328889
[TBL] [Abstract][Full Text] [Related]
6. Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro.
Bymaster FP; Nelson DL; DeLapp NW; Falcone JF; Eckols K; Truex LL; Foreman MM; Lucaites VL; Calligaro DO
Schizophr Res; 1999 May; 37(1):107-22. PubMed ID: 10227113
[TBL] [Abstract][Full Text] [Related]
7. Effects of olanzapine and betahistine co-treatment on serotonin transporter, 5-HT2A and dopamine D2 receptor binding density.
Lian J; Huang XF; Pai N; Deng C
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Dec; 47():62-8. PubMed ID: 23994047
[TBL] [Abstract][Full Text] [Related]
8. Regulation of plasma glucose levels by central dopamine D
Ikeda H; Mikami R; Yonemochi N; Waddington JL
Eur J Pharmacol; 2023 Oct; 956():175984. PubMed ID: 37567458
[TBL] [Abstract][Full Text] [Related]
9. Olanzapine increases AMPK-NPY orexigenic signaling by disrupting H1R-GHSR1a interaction in the hypothalamic neurons of mice.
Chen X; Yu Y; Zheng P; Jin T; He M; Zheng M; Song X; Jones A; Huang XF
Psychoneuroendocrinology; 2020 Apr; 114():104594. PubMed ID: 32007669
[TBL] [Abstract][Full Text] [Related]
10. Crosstalk of hypothalamic chemerin, histamine, and AMPK in diet-and olanzapine-induced obesity in rats.
Samy DM; Mostafa DK; Abdelmonsif DA; Ismail CA; Hassaan PS
Life Sci; 2021 Nov; 284():119897. PubMed ID: 34450172
[TBL] [Abstract][Full Text] [Related]
11. Olanzapine-activated AMPK signaling in the dorsal vagal complex is attenuated by histamine H1 receptor agonist in female rats.
He M; Zhang Q; Deng C; Wang H; Huang XF
Endocrinology; 2014 Dec; 155(12):4895-904. PubMed ID: 25264935
[TBL] [Abstract][Full Text] [Related]
12. AICAR Prevents Acute Olanzapine-Induced Disturbances in Glucose Homeostasis.
Bush ND; Townsend LK; Wright DC
J Pharmacol Exp Ther; 2018 Jun; 365(3):526-535. PubMed ID: 29581153
[TBL] [Abstract][Full Text] [Related]
13. The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063.
Assié MB; Carilla-Durand E; Bardin L; Maraval M; Aliaga M; Malfètes N; Barbara M; Newman-Tancredi A
Eur J Pharmacol; 2008 Sep; 592(1-3):160-6. PubMed ID: 18640111
[TBL] [Abstract][Full Text] [Related]
14. Alpha1-adrenergic, D1, and D2 receptors interactions in the prefrontal cortex: implications for the modality of action of different types of neuroleptics.
Gioanni Y; Thierry AM; Glowinski J; Tassin JP
Synapse; 1998 Dec; 30(4):362-70. PubMed ID: 9826228
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of antipsychotic-like effects by combined treatment with the alpha1-adrenoceptor antagonist prazosin and the dopamine D2 receptor antagonist raclopride in rats.
Wadenberg ML; Hertel P; Fernholm R; Hygge Blakeman K; Ahlenius S; Svensson TH
J Neural Transm (Vienna); 2000; 107(10):1229-38. PubMed ID: 11129112
[TBL] [Abstract][Full Text] [Related]
16. The role of hypothalamic H1 receptor antagonism in antipsychotic-induced weight gain.
He M; Deng C; Huang XF
CNS Drugs; 2013 Jun; 27(6):423-34. PubMed ID: 23640535
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of the central hyperglycemic action of histamine in mice.
Nishibori M; Itoh Y; Oishi R; Saeki K
J Pharmacol Exp Ther; 1987 May; 241(2):582-6. PubMed ID: 3572814
[TBL] [Abstract][Full Text] [Related]
18. Atypical antipsychotics and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor binding on insulin secretion in vivo: an animal model.
Hahn M; Chintoh A; Giacca A; Xu L; Lam L; Mann S; Fletcher P; Guenette M; Cohn T; Wolever T; Arenovich T; Remington G
Schizophr Res; 2011 Sep; 131(1-3):90-5. PubMed ID: 21696923
[TBL] [Abstract][Full Text] [Related]
19. Descending modulation of neuropathic hypersensitivity by dopamine D2 receptors in or adjacent to the hypothalamic A11 cell group.
Wei H; Viisanen H; Pertovaara A
Pharmacol Res; 2009 May; 59(5):355-63. PubMed ID: 19416636
[TBL] [Abstract][Full Text] [Related]
20. Benzo- and thienobenzo- diazepines: multi-target drugs for CNS disorders.
Mendonça Júnior FJ; Scotti L; Ishiki H; Botelho SP; Da Silva MS; Scotti MT
Mini Rev Med Chem; 2015; 15(8):630-47. PubMed ID: 25694077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
